Vol 56(2022) N 4 p. 508-516; DOI 10.1134/S0026893322040112
A.S. Tikhonov1*, R.R. Mintaev1,2, D.V. Glazkova1, E.V. Bogoslovskaya1, G.A. Shipulin1
HIV Restriction Factor APOBEC3G and Prospects for Its Use in Gene Therapy for HIV1Center for Strategic Planning and Management of Medical and Biological Health Risks, Moscow, 119833 Russia
2Mechnikov Research Institute of Vaccines and Sera, Moscow, 105064 Russia
Received - 2021-11-27; Revised - 2022-02-11; Accepted - 2022-02-17
The mechanisms for the protection of the human body from viral or bacterial agents are extremely diverse. In one such mechanism, an important role belongs to the cytidine deaminase APOBEC3 family, which is the factor of congenital immunity and protects the organism from numerous viral agents. One of the proteins of this family, APOBEC3G, is able to protect against Human Immunodeficiency Virus type 1 in the absence of viral protein Vif. In turn, Vif opposes APOBEC3G action, causing polyubiquity of the protein and degradation in the proteasome. The review describes possible ways to increase the anti-HIV activity of APOBEC3G, giving it resistance to viral protein Vif, as well as potential approaches to the use of modified APOBEC3G in gene therapy for HIV.
APOBEC3G, APOBEC3G-D128K, gene therapy, HIV infection, Vif